These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 31150120)

  • 21. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
    Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
    Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
    de Castro Junior G; Segalla JG; de Azevedo SJ; Andrade CJ; Grabarz D; de Araújo Lima França B; Del Giglio A; Lazaretti NS; Álvares MN; Pedrini JL; Kussumoto C; de Matos Neto JN; Forones NM; Fernandes Júnior HJ; Borges G; Girotto G; da Silva IDCG; Maluf-Filho F; Skare NG
    Eur J Cancer; 2018 Jan; 88():21-30. PubMed ID: 29179134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
    Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
    Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
    Tao Y; Sun XS; Pointreau Y; Le Tourneau C; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Calderon B; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Damstrup L; Crompton P; Ennaji A; Gollmer K; Nauwelaerts H; Bourhis J
    Eur J Cancer; 2023 Apr; 183():24-37. PubMed ID: 36796234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Zheng B; He M; Han Y; Jiang X; Ou X; Zhang P; Guo R; Li J; Zhang X; Qiao Q; Wu H; Hu M; Feng M; Tu W; Yi J
    Curr Cancer Drug Targets; 2024; 24(9):952-966. PubMed ID: 38549541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
    Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C
    BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
    Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.
    Hughes RT; Porosnicu M; Levine BJ; Lycan TW; Shenker RF; Frizzell BA; Greven KM
    J Med Imaging Radiat Oncol; 2021 Oct; 65(6):796-805. PubMed ID: 34309212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
    Cao Y; Deng L; Lian S; Jiang Y
    J BUON; 2019; 24(5):2013-2019. PubMed ID: 31786869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
    Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
    Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
    Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
    Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
    BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
    Gao M; Yuan T; Zhang F
    J BUON; 2021; 26(1):116-123. PubMed ID: 33721441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
    Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
    J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.